Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lyso-glycosphingolipids: presence and consequences
Marco van Eijk, Maria J. Ferraz, Rolf G. Boot, et al.
Essays in Biochemistry (2020) Vol. 64, Iss. 3, pp. 565-578
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Don’t Be Surprised When These Surprise You: Some Infrequently Studied Sphingoid Bases, Metabolites, and Factors That Should Be Kept in Mind During Sphingolipidomic Studies
Alfred H. Merrill
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 650-650
Open Access | Times Cited: 2
Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions
Ken Kok, Kimberley C. Zwiers, Rolf G. Boot, et al.
Biomolecules (2021) Vol. 11, Iss. 2, pp. 271-271
Open Access | Times Cited: 92
Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models
Hoa Tt Ha, S. Liu, Xuan Ta Nguyen, et al.
JCI Insight (2024)
Open Access | Times Cited: 12
Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
Andrea Dardis, Helen Michelakakis, Paula Rozenfeld, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 30
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial
Raphael Schiffmann, Timothy M. Cox, Jean-François Dedieu, et al.
Brain (2022) Vol. 146, Iss. 2, pp. 461-474
Open Access | Times Cited: 29
The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBA
Eddie Pradas, Marta Martínez‐Vicente
Cells (2023) Vol. 12, Iss. 1, pp. 191-191
Open Access | Times Cited: 20
The Unique Phenotype of Lipid-Laden Macrophages
Marco van Eijk, Johannes M. F. G. Aerts
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4039-4039
Open Access | Times Cited: 39
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
Matthew Surface, Manisha Balwani, Cheryl Waters, et al.
Movement Disorders (2021) Vol. 37, Iss. 2, pp. 416-421
Open Access | Times Cited: 34
Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?
Giovanni Bertoldi, Ilaria Caputo, Giulia Driussi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 2063-2063
Open Access | Times Cited: 13
Sex Differences in Circulating Inflammatory, Immune, and Tissue Growth Markers Associated with Fabry Disease-Related Cardiomyopathy
Margarita M. Ivanova, Julia Dao, Andrew Friedman, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 322-322
Open Access
Cultured Macrophage Models for the Investigation of Lysosomal Glucocerebrosidase and Gaucher Disease
Max Louwerse, Kateryna O. Bila, Martijn J. C. van der Lienden, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2726-2726
Open Access
Sphingolipidoses: expanding the spectrum of α-synucleinopathies
Daniel Erskine, Agnieszka K. Bronowska, Tiago F. Outeiro, et al.
Journal of Neural Transmission (2025)
Open Access
The Bioactive Sphingolipid Playbook. A Primer for the Uninitiated as well as Sphingolipidologists
Yusuf A. Hannun, Alfred H. Merrill, Chiara Luberto
Journal of Lipid Research (2025), pp. 100813-100813
Open Access
C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages
Jacquelyn Serfecz, Afsoon Saadin, Clayton P. Santiago, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9912-9912
Open Access | Times Cited: 24
Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients
Richard W.D. Welford, Hervé Farine, Michel A. Steiner, et al.
Molecular Genetics and Metabolism Reports (2022) Vol. 30, pp. 100843-100843
Open Access | Times Cited: 18
The structural diversity of natural glycosphingolipids (GSLs)
Zhongwu Guo
Journal of Carbohydrate Chemistry (2022) Vol. 41, Iss. 2-3, pp. 63-154
Open Access | Times Cited: 17
Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson’s disease
Manoj Kumar, Manasa P. Srikanth, Michela Deleidi, et al.
Human Molecular Genetics (2023) Vol. 32, Iss. 11, pp. 1888-1900
Open Access | Times Cited: 10
Neuronopathic Gaucher disease: Rare in the West, common in the East
Özlem Göker-Alpan, Margarita M. Ivanova
Journal of Inherited Metabolic Disease (2024) Vol. 47, Iss. 5, pp. 917-934
Open Access | Times Cited: 3
A novel brain-penetrant oral UGT8 inhibitor decreases in vivo galactosphingolipid biosynthesis in murine Krabbe disease
Eva Zaccariotto, María Begoña Cachón-González, Bing Wang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 149, pp. 112808-112808
Open Access | Times Cited: 14
Rare lysosomal disease registries: lessons learned over three decades of real-world evidence
Pramod K. Mistry, Priya S. Kishnani, Christoph Wanner, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Spinal muscular atrophy-like phenotype in a mouse model of acid ceramidase deficiency
Murtaza S. Nagree, Jitka Rybová, Annie Kleynerman, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 7
A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease
Takahiro Fujii, Yuta Tanaka, Hideyuki Oki, et al.
Journal of Neurochemistry (2021) Vol. 159, Iss. 3, pp. 543-553
Open Access | Times Cited: 16
Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1
Timothy M. Cox, Joel Charrow, Elena Lukina, et al.
Genetics in Medicine (2022) Vol. 25, Iss. 2, pp. 100329-100329
Open Access | Times Cited: 12
LysoGb3 quantification facilitates phenotypic categorization of Fabry disease patients: Insights gained by a novel MS/MS method
Ladislav Kuchař, Linda Berná, Helena Poupětová, et al.
Clinica Chimica Acta (2024) Vol. 561, pp. 119824-119824
Open Access | Times Cited: 2
Fabry nephropathy: a treatable cause of chronic kidney disease
Michael L. West, Laurette Geldenhuys, Daniel G. Bichet
Rare Disease and Orphan Drugs Journal (2024) Vol. 3, Iss. 3
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top